TCGA-E2-A1B4-01A-11R-A12P-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 33
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.340
- ESTROGEN_RESPONSE_EARLY+0.130
- P53_PATHWAY+0.120
- DNA_REPAIR+0.110
- FATTY_ACID_METABOLISM+0.090
- BILE_ACID_METABOLISM+0.060
- ESTROGEN_RESPONSE_LATE+0.050
- PEROXISOME+0.050
- APICAL_SURFACE+0.040
- ADIPOGENESIS+0.010
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.580
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.430
- INFLAMMATORY_RESPONSE-0.430
- MITOTIC_SPINDLE-0.420
- INTERFERON_ALPHA_RESPONSE-0.390
- COMPLEMENT-0.370
- MYC_TARGETS_V2-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.912 |
| 2 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.890 |
| 3 | ERR2278853 | — | — | 0.888 |
| 4 | TCGA-AO-A125-01A-11R-A10J-07 | — | B | 0.885 |
| 5 | SJEPD001522_R1.RNA-Seq | EPN | EPN Tumor | 0.879 |
| 6 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.879 |
| 7 | SRR6079984 | — | — | 0.872 |
| 8 | SRR2016961 | — | — | 0.872 |
| 9 | TCGA-BH-A0HN-01A-11R-A10U-07 | — | B | 0.867 |
| 10 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |